Predicting and detecting prostate cancer metastasis before it is clinically evident

Arkaitz Carracedo

  • PROJECT LEADER

    Arkaitz Carracedo

  • HOST ORGANIZATION, COUNTRY

    Centro de Investigación Cooperativa en Biociencias (CIC bioGUNE), Spain

  • DESCRIPTION

    Metastasis is the main cause of death in oncological diseases. In the context of prostate cancer, a percentage of patients relapse after first-line localized treatment, and present a high risk of failing in later therapies and developing metastasis.

    It is currently very difficult to anticipate metastasis or to detect it early in order to slow the progression of the disease. This project is based on the identification of the characteristics of the prostate tumor that informs about its early spread. In addition, it is proposed to exploit this knowledge to develop new metastasis imaging technologies and strategies for treatment against the disseminated disease. The goal is to identify patients with high risk of metastasis and to implement clinical guidelines to improve treatment.

  • CONSORTIUM
    (PRINCIPAL INVESTIGATOR, ORGANIZATION, COUNTRY)

    • Christian Frezza, University of Cambridge, UK

    • Mireia Castillo-Martín, Fundação Champalimaud, Portugal

    • Jordi Llop, CIC biomaGUNE, Spain

    • Ana Loizaga Iriarte, Basurto Hospital, Spain

  • PROJECT TITLE

    Eradicating prostate cancer metastasis before clinical manifestation

  • BUDGET

    €499,915